Bioaccessibility and Pharmacokinetics of a Commercial Saffron (Crocus sativus L.) Extract
Table 2
Bioactive molecules content expressed as percentage (%, dry basis) found in affron® before and after in vitro digestion process at salivary, gastric, and duodenal steps.
Bioactive components
Initial sample
Digested sample
Bioaccessibility
Salivary
Gastric
Duodenal
Safranal
0.04 ± 0.01a
0.03 ± 0.00a
0.21 ± 0.01c
0.08 ± 0.01b
200.00
t-crocin-4
1.66 ± 0.04b
1.11 ± 0.43b
0.26 ± 0.03a
0.20 ± 0.04a
12.05
Total crocins
3.63 ± 0.05b
3.43 ± 0.12b
1.87 ± 0.35a
1.48 ± 0.22a
40.77
Kaempferol diglucoside
0.13 ± 0.01b,c
0.14 ± 0.01c
0.12 ± 0.01b
0.09 ± 0.01a
69.23
Picrocrocin
3.21 ± 0.07c
3.14 ± 0.11c
2.07 ± 0.02a
2.61 ± 0.05b
81.31
Crocetin
0.03 ± 0.01a
0.02 ± 0.01a
0.03 ± 0.01a
0.02 ± 0.01a
66.67
Data are represented as mean ± SD. Different letters within a column (a–c) indicate significant differences of the bioactive component of affron® in every step during the digestion process.